Omri Amirav-Drory

Board Observer at C2i Genomics

Omri Amirav-Drory is a Board Observer at C2i Genomics. Prior to this, they were the CEO of resistanceBio.

Omri has also held positions at Talus Bio, La Jolla Labs, Mana.bio, PANGEA Therapeutics, Pepper Bio, Nanocarry Therapeutics, Gilboa Therapeutics, and NFX.

Omri Amirav-Drory has a postdoctoral degree in biochemistry and molecular biology from Stanford University, a PhD in biochemistry from Tel Aviv University, and a BS in biochemistry and molecular biology from Tel Aviv University.

Org chart

Eli Casdin

Director

James Currier

Board Observer

Alex Parker

Independent Director

David Sidransky

Scientific Advisory Board Member

Shaun Rodriguez

Director

Matija Snuderl

Scientific Advisory Board Member

Anna Turetsky

Board Observer

Dan Landau

Scientific Advisory Board Member

Teams

+10

Board of Directors

13 members

Timeline

  • Board Observer

    Current role